Alnara Pharmaceuticals, Inc., a Cambridge, Massachusetts-based pharmaceutical company developing protein therapeutics for the treatment of metabolic diseases, has secured $35m in Series B venture capital financing.
The round was led by new investor MPM Capital, joined by current investors Third Rock Ventures, Frazier Healthcare and Bessemer Venture Partners.
In conjunction with the investment, MPM managing director Ashley Dombkowski, Ph.D., will join the company’s board of directors.
Alnara’s lead product is liprotamase, a novel, non-porcine pancreatic enzyme replacement therapy, which has completed Phase 3 clinical development in collaboration with the Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT).
The capital infusion will enable the company to continue to advance the regulatory filings, commercial planning and launch preparation efforts in support of liprotamase.
Alnara also plans to use proceeds to finalize development of a novel pediatric formulation which meets a significant unmet need in patients with cystic fibrosis (CF).